Key result
Transcatheter aortic valve implantation significantly reduced 1-year mortality compared to standard therapy in high-risk patients with severe aortic stenosis, and demonstrated non-inferiority to surgical aortic valve replacement.
Hazard Ratio: 0.55 (95% CI 0.4–0.74)
Absolute Event Rate: 30.7% vs 50.7%
p-value: p=<0.001
Surgical aortic valve replacement remains the gold standard for aortic stenosis, but TAVI is an effective alternative for high-risk patients.
May support TAVI in high-risk severe aortic stenosis; leaves open durability and lower-risk expansion.
Aortic Stenosis (AS) is present in approximately 2% of people and is most commonly caused by degenerative calcification of the aortic valve. Without aortic valve intervention, aortic stenosis is associated with substantial morbidity and mortality in patients, particularly in those presenting with angina, syncope, or heart failure.
No takes yet. Share an insight, caveat, or question.
Tarek Malas (2013) conducted a review in Aortic Stenosis. Transcatheter Aortic Valve Implantation (TAVI) vs. Standard medical therapy or Surgical Aortic Valve Replacement (SAVR) was evaluated on Death from any cause at 1 year (TAVI vs standard therapy, PARTNER trial) (HR 0.55, 95% CI 0.4-0.74, p=<0.001). Transcatheter aortic valve implantation significantly reduced 1-year mortality compared to standard therapy in high-risk patients with severe aortic stenosis, and demonstrated non-inferiority to surgical aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: